SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Stifel 2026 Healthcare Conference, Truist 2026 BioPharma Symposium, UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, and the Piper Sandler 38th Annual Healthcare Conference in November and December.
Details of the company's participation are as follows:
- Stifel 2026 Healthcare Conference
Details: Viking management will participate in a fireside chat and investor meetings.
Conference Dates: November 10-12, 2026
Fireside Chat Date/Time: Wednesday, November 11th, 10:40 am â 11:10 am ET
Location: New York, NY
- Truist 2026 BioPharma Symposium
Details: Viking management will participate in investor meetings.
Conference Date: November 12, 2026
Location: New York, NY
- UBS Global Biopharma Conference
Details: Viking management will participate in a fireside chat and investor meetings.
Conference Dates: November 16-17, 2026
Fireside Chat Date/Time: Tuesday, November 17th, 10:40 am - 11:10 am ET
Location: London, UK
- Jefferies Global Healthcare Conference
Details: Viking management will participate in a fireside chat and investor meetings.
Conference Dates: November 16-19, 2026
Fireside Chat Date/Time: Wednesday, November 18th, 2:00 pm â 2:25 pm GMT
Location: London, UK
Webcast available
- Piper Sandler 38th Annual Healthcare Conference
Details: Viking management will participate in a fireside chat and investor meetings.
Conference Dates: December 1-3, 2026
Fireside Chat Date/Time: Wednesday, December 2nd, 2:00 pm - 2:25 pm ET
Location: New York, NY
Webcast available
A live webcast of the Jefferies and Piper Sandler fireside chats may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Guided by deep expertise in metabolic biology and rigorous science, Viking is developing innovative treatments to help people achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, along with maintenance dosing strategies designed to support long-term weight management. Viking is also advancing additional obesity programs, including VK3019, an amylin receptor agonist, VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD).
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
SOURCE Viking Therapeutics, Inc.
Share this article